title: [Combined therapy of malignant tumors of the upper jaw and nasal cavity using pre- and post-operative radiation with metronidazol radiomodification].
abstract: Seventy-five patients with malignant tumors of the upper jaw and nasal cavity have received combination therapy. Administration of metronidasol (5-8 g/m2 body surface) in combination with large doses of preoperative radiation was shown to significantly improve 3-year total and recurrence-free survival-from 50 to 60% and 32 to 57%, respectively. As a result, no postoperative radiotherapy was required. Postoperative radiation treatment is indicated when means of radiosensibilization are not used. The use of radiomodifiers is mandatory in combination therapy of non-differentiated cell carcinoma, cylindroma, transitory-cell papilloma and non-epithelial neoplasms.
authors.forename: V G
authors.initials: VG
authors.lastname: Andreev
authors.forename: I S
authors.initials: IS
authors.lastname: Mardynskiĭ
authors.forename: N G
authors.initials: NG
authors.lastname: Molotkova
authors.forename: V A
authors.initials: VA
authors.lastname: Pankratov
authors.forename: A V
authors.initials: AV
authors.lastname: Iglin
authors.forename: I S
authors.initials: IS
authors.lastname: Romanko
authors.forename: M U
authors.initials: MU
authors.lastname: Radzhanova
mesh_terms: D017024:Chemotherapy, Adjuvant; D005500:Follow-Up Studies; D006801:Humans; D007573:Jaw Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008795:Metronidazole / Q000627:therapeutic use*; D009296:Nasal Cavity; D009669:Nose Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D018714:Radiotherapy, Adjuvant; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D011838:Radiation-Sensitizing Agents; D008795:Metronidazole